Olsson, Sarah
Talley, Nicholas J.
Holtmann, Gerald
Funding for this research was provided by:
National Health and Medical Research Council (CRE Digestive Health)
The University of Queensland
Article History
Accepted: 10 June 2022
First Online: 27 July 2022
Compliance with Ethical Standards
:
: Sarah Ollsson declares no conflict of interest. Gerald Holtmann reports to be on the advisory boards Australian Biotherapeutics, Glutagen, Bayer, and received research support from Bayer, Abbott, Pfizer, Janssen, Takeda and Allergan. He serves on the Boards of the West Moreton Hospital and Health Service, Queensland; UQ Healthcare, Brisbane; and the Gastro-Liga, Germany and the advisory Board of Servatus. He has a patent for the Brisbane aseptic biopsy device and serves as Editor of the Gastro-Liga Newsletter. GH acknowledges funding from the National Health and Medical Research Council (NHMRC) for the Centre for Research Excellence in Digestive Health. GH holds an NHMRC Ideas and one MRFF grant. Nicholas J. Talley reports personal fees from Allakos, from Aviro Health, from Antara Life Sciences, from Arlyx from Bayer, from Danone, from Planet Innovation, from Takeda, from Viscera Labs, from twoXAR, from Viscera Labs, from Dr Falk Pharma, from Censa, from Cadila Pharmaceuticals, from Progenity Inc., from Sanofi-Aventis, from Glutagen, from ARENA Pharmaceuticals, from IsoThrive, from BluMaiden, and from HVN National Science Challenge, and non-financial support from HVN National Science Challenge NZ, outside the submitted work; in addition, NJT has a patent Biomarkers of IBS licenced (no. 12735358.9–1405/2710383 and (no. 12735358.9–1405/2710384), a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licenced to Mayo/Talley, a patent Nestec European Patent licenced and a patent Singapore Provisional Patent NTU Ref: TD/129/17 “Microbiota Modulation Of BDNF Tissue Repair Pathway” issued and copyright Nepean Dyspepsia Index (NDI) 1998 and Editorial: Medical Journal of Australia (Editor in Chief), Up to Date (Section Editor), Precision and Future Medicine, Sungkyunkwan University School of Medicine, South Korea, Med (Journal of Cell Press). NJT participates in committees: Australian Medical Council (AMC) Council Member (2016–2019), MBS Review Taskforce (2016–2020), NHMRC Principal Committee, Research Committee (2016–2021), Asia Pacific Association of Medical Journal Editors (APAME) (current), GESA Board Member (2017–2019). NJT Misc: Avant Foundation (judging of research grants) (2019). NJT community and patient advocacy groups: Advisory Board, IFFGD (International Foundation for Functional GI Disorders). NJT acknowledges funding from the National Health and Medical Research Council (NHMRC) for the Centre for Research Excellence in Digestive Health. NJT holds an NHMRC Investigator grant.
: This article does not contain any studies with human or animal subjects performed by any of the authors.